drugset / Trial / NCT00044785

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

NCT00044785 ↗

Phase 1 Terminated 24 enrolled Wellstat Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential. It is hypothesized that adding PN401 to the CPT-11, 5FU, leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well tolerated and therefore potentially increase effectiveness.

Timeline

Start
2002-08
Primary completion
—
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule — —
Subject fluorouracil Small molecule — —
Background Leucovorin Small molecule — —
Background triacetyluridine Unknown — —

Indications